MOLECULAR DOCKING AND ADMET STUDY OF COUMARINS EXPLORING THEIR POTENTIAL AS TREATMENTS FOR ALZHEIMER 'S DISEASE

Alzheimer's disease (AD) is a neurological illness that affects older individuals and manifests as memory loss, cognitive decline, and linguistic impairment. As per the cholinergic theory, AD is mostly associated with a drop in acetylcholine (AChE) levels in the brain due to damage to cholinergic neurons. Therefore, increasing AChE with acetylcholinesterase inhibition is one of the most effective ways to treat AD symptoms. Sonmez et al.[42] A class of physical and cognitive impairments known as neurodegenerative diseases are brought on by the death of brain neurons. The most prevalent ND, Alzheimer's disease has been diagnosed in over 30 million people worldwide. Its symptoms, which start with recurrent short-term memory loss and advance to the degradation of higher cognitive skills including language and decision-making, are progressive and permanent. The disease has a significant social and economic impact because of the nature of these symptoms. This neurodegeneration is the consequence of several interconnected pathways supported by genetic and environmental variables rather than a single cause or process. Treatment has become challenging because of this intricate pathophysiology, and the medications currently on the market mainly relieve symptoms. Mzezewa et al.[33] Alois Alzheimer, a German neuro scientist, told about the Alzheimer’s disease in 1907. One of his patients had cognitive impairment, behavioral issues, and memory loss. Deficiencies. A biopsy revealed significant brain damage, including ageing plaques, neuron muddle known as neurofibrillary Muddle and axis. lack of Nerve cell and synapses, primarily in the hippocampus and neocortex association regions. The Pathophysiology of Alzheimer's disease begins with hippocampal shrinkage About 80% of people 65 and older have Alzheimer's; dementia only affects a small percentage of people at this age, but the frequency of dementia in Alzheimer's rises to 25% in people 80 and older. In older adults, Alzheimer's disease (AD) is the most common cause of dementia., and it is typified by growing neurological changes. De et al.[12]

Authors

Publication Details

Journal
World Journal of Pharmaceutical Research
Published
2026-10-16
DOI
https://doi.org/10.5281/zenodo.23385062
Primary Topic
Cholinesterase and Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MOLECULAR DOCKING AND ADMET STUDY OF COUMARINS EXPLORING THEIR POTENTIAL AS TREATMENTS FOR ALZHEIMER 'S DISEASE

*Devendra Kumar
World Journal of Pharmaceutical Research
Cholinesterase and Neurodegenerative Diseases
article

MOLECULAR DOCKING AND ADMET STUDY OF COUMARINS EXPLORING THEIR POTENTIAL AS TREATMENTS FOR ALZHEIMER 'S DISEASE

*Devendra Kumar
article en

Abstract

Alzheimer's disease (AD) is a neurological illness that affects older individuals and manifests as memory loss, cognitive decline, and linguistic impairment. As per the cholinergic theory, AD is mostly associated with a drop in acetylcholine (AChE) levels in the brain due to damage to cholinergic neurons. Therefore, increasing AChE with acetylcholinesterase inhibition is one of the most effective ways to treat AD symptoms. Sonmez et al.[42] A class of physical and cognitive impairments known as neurodegenerative diseases are brought on by the death of brain neurons. The most prevalent ND, Alzheimer's disease has been diagnosed in over 30 million people worldwide. Its symptoms, which start with recurrent short-term memory loss and advance to the degradation of higher cognitive skills including language and decision-making, are progressive and permanent. The disease has a significant social and economic impact because of the nature of these symptoms. This neurodegeneration is the consequence of several interconnected pathways supported by genetic and environmental variables rather than a single cause or process. Treatment has become challenging because of this intricate pathophysiology, and the medications currently on the market mainly relieve symptoms. Mzezewa et al.[33] Alois Alzheimer, a German neuro scientist, told about the Alzheimer’s disease in 1907. One of his patients had cognitive impairment, behavioral issues, and memory loss. Deficiencies. A biopsy revealed significant brain damage, including ageing plaques, neuron muddle known as neurofibrillary Muddle and axis. lack of Nerve cell and synapses, primarily in the hippocampus and neocortex association regions. The Pathophysiology of Alzheimer's disease begins with hippocampal shrinkage About 80% of people 65 and older have Alzheimer's; dementia only affects a small percentage of people at this age, but the frequency of dementia in Alzheimer's rises to 25% in people 80 and older. In older adults, Alzheimer's disease (AD) is the most common cause of dementia., and it is typified by growing neurological changes. De et al.[12]

World Journal of Pharmaceutical Research
Good health and well-being
Openalex Percentile: Top 15%
Cholinesterase and Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.